Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea

SIMPLE SUMMARY: Recently, selpercatinib, a highly selective inhibitor of RET receptor tyrosine kinase, has been used for RET-altered thyroid cancer. However, real-world data of its effectiveness and safety in various clinical situations are lacking. We present four cases of patients with advanced th...

Descripción completa

Detalles Bibliográficos
Autores principales: Baek, Han-Sang, Ha, Jeonghoon, Ha, Seunggyun, Bae, Ja Seong, Jung, Chan Kwon, Lim, Dong-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046919/
https://www.ncbi.nlm.nih.gov/pubmed/36975442
http://dx.doi.org/10.3390/curroncol30030229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046919/
https://www.ncbi.nlm.nih.gov/pubmed/36975442
http://dx.doi.org/10.3390/curroncol30030229

Ejemplares similares